Metabolism - Clinical and Experimental
Volume 52, Issue 3 , Pages 264-272 , March 2003

Chronic effects of dehydroepiandrosterone on rat adipose tissue metabolism

Received 4 August 2000 ,Accepted 17 September 2002.

References 

  1. Nestler JE, Clore JN, Blackard WG. Dehydroepiandrosterone: The “missing link” between hyperinsulinemia and atherosclerosis?. FASEB J. 1992;6:3073–3075
  2. Berdanier CD, Parente JA, McIntosh MK. Is dehydroepiandrosterone an antiobesity agent?. FASEB J. 1993;7:414–419
  3. Clore JN. Dehydroepiandrosterone and body fat. Obes Res. 1995;3(suppl 4):613S–616S
  4. Cleary MP. The antiobesity effects of dehydroepiandrosterone in rats. Proc Soc Exp Biol Med. 1991;196:8–16
  5. Taniguchi S, Yanase T, Haji M, et al.  The antiobesity effect of dehydroepiandrosterone in castrated or noncastrated obese Zucker male rats. Obes Res. 1995;3(suppl 5):639S–643S
  6. Han D-H, Hansen PA, Chen MM, et al.  DHEA treatment reduces fat accumulation and protects against insulin resistance in male rats. J Gerontol Biol Sci. 1998;53:B19–B24
  7. Tagliaferro AR, Ronan AM, Payne J, et al.  Increased lipolysis to β-adrenergic stimulation after dehydroepiandrosterone treatment in rats. Am J Physiol. 1995;268:R1374–R1380
  8. Lea-Currie YR, Wu SM, McIntosh MK. Effects of acute administration of dehydroepiandrosterone-sulfate on adipose tissue mass and cellularity in male rats. Int J Obes Relat Metab Dis. 1997;21:147–154
  9. Lea-Currie YR, Wen P, McIntosh MK. Dehydroepiandrosterone-sulfate (DHEAS) reduces adipocyte hyperplasia associated with feeding rats a high fat diet. Int J Obes Relat Metab Dis. 1997;21:1058–1064
  10. Arner P, Eckel RH. Adipose tissue as a storage organ. In:  Bray GA,  Bouchard C,  James WPT editor. Handbook of Obesity. New York, NY: Dekker; 1998;p. 379–395
  11. Langin D, Holm C, Lafontan M. Adipocyte hormone-sensitive lipase: A major regulator of lipid metabolism. Proc Nutr Soc. 1996;55:93–109
  12. Lafontan M, Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res. 1993;34:1057–1091
  13. Degerman E, Smith CJ, Tornqvist H, et al.  Evidence that insulin and isoprenaline activate the cGMP-inhibited low-Km cAMP-phosphodiesterase in rat fat cells by phosphorylation. Proc Natl Acad Sci USA. 1990;7:533–537
  14. Mortola JF, Yen SSC. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab. 1990;71:696–704
  15. Morales AJ, Nolan JJ, Nelson JC, et al.  Effects of replacement dose of dehydroepiandrosterone in men and women with advancing age. J Clin Endocrinol Metab. 1994;78:1360–1367
  16. Diamond P, Cusan L, Gomez JL, et al.  Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol. 1996;150(suppl):S43–S50
  17. Labrie F, Diamond P, Cusan L, et al.  Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab. 1997;82:3498–3505
  18. Labrie C, Flamand M, Bélanger A, et al.  High bioavailability of dehydroepiandrosterone administered percutaneously in the rat. J Endocrinol. 1996;150(suppl):S107–S118
  19. Martel C, Sourla A, Pelletier G, et al.  Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J Endocrinol. 1997;157:433–442
  20. Ke HZ, Paralkar VM, Grasser WA, et al.  Effects of CP-336,156, a new nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models. Endocrinology. 1998;139:2068–2076
  21. Bérubé R, Malenfant J, Gauvin D, et al.  Quantitation of androgenic and estrogenic steroids in rat and monkey serum using gas chromatography and negative chemical ionization mass spectrometry. In: Proceedings of the 48th ASMS Conference on Mass Spectrometry and Allied Topics, Long Beach, CA. 2000;
  22. Savard R, Deshaies Y, Després JP, et al.  Lipogenesis and lipoprotein lipase in human adipose tissue. Reproducibility of measurements and relationships with fat cell size. Can J Physiol Pharmacol. 1984;62:1448–1452
  23. Solomon SS. Phosphodiesterase activity of rat and human adipose tissue. J Lab Clin Med. 1972;79:598–610
  24. DeMazancourt P, Giudicelli Y. Guanine nucleotides and adenosine “Ri”-site analogues stimulate the membrane-bound low Km cyclic AMP phosphodiesterase of rat adipocytes. FEBS Lett. 1984;173:385–388
  25. Lowry OH, Rosebrough NJ, Farr AL, et al.  Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275
  26. Fredriksson G, Stralfors P, Nilsson NO, et al.  Hormone-sensitive lipase from rat. Methods Enzymol. 1981;71:636–646
  27. Frayn KN, Langin D, Holm C, et al.  Hormone-sensitive lipase: quantitation of enzyme activity and mRNA level in small biopsies of human adipose tissue. Clin Chim Acta. 1993;216:183–189
  28. Mauriège P, Imbeault P, Langin D, et al.  Regional and gender variations in adipose tissue lipolysis in response to weight loss. J Lipid Res. 1999;40:1559–1571
  29. Mauriège P, Atgié C, Simard PM, et al.  Major lipolytic defects in white adipocytes from different depots of a new model of type II diabetes: The obese SHR/N-cp rat. Obes Res. 1995;3:630s; (abstr)
  30. Tavernier G, Galitzky J, Valet P, et al.  Molecular mechanisms underlying regional variations of catecholamine-induced lipolysis in rat adipocytes. Am J Physiol. 1995;268:E1135–E1142
  31. Lacasa D, Agli B, Giudicelli Y. Direct assessment of beta-adrenergic receptors in intact rat adipocytes by binding of [3H]-CGP 12177. Evidence for agonist high affinity complex and for β1- and β2-receptor subtypes. Eur J Biochem. 1985;146:339–346
  32. Mauriège P, de Pergola G, Berlan M, et al.  Human fat cell beta-adrenergic receptors: beta-agonist dependent lipolytic responses and characterization of beta-adrenergic binding sites on human fat cell membranes with highly selective beta1-antagonists. J Lipid Res. 1988;29:587–601
  33. D'Allaire F, Atgié C, Mauriège P, et al.  Characterization of β1- and β3-adrenoceptors in intact brown adipocytes. Br J Pharmacol. 1995;114:275–282
  34. Rebuffé-Scrive M. Sex steroid hormones and adipose tissue metabolism in ovariectomized rats. Acta Physiol Scand. 1987;129:471–477
  35. Deshaies Y, Dagneault A, Richard D. Tissue- and gender-specific modulation of lipoprotein lipase in intact and gonadectomised rats treated with dl-fenfluramine. Int J Obes. 1994;18:405–411
  36. Lacasa D, Agli B, Giudicelli Y. Hormonal activation of the cGMP-inhibited low-Km cyclic AMP phosphodiesterase of rat adipocytes from different sites: Influence of ovariectomy. Biochim Biophys Acta. 1992;1136:99–104
  37. de Pergola G, Holmang A, Svedberg J, et al.  Testosterone treatment of ovariectomized rats: Effects on lipolysis regulation in adipocytes. Acta Endocrinol. 1990;123:61–66
  38. Simard PM, Atgié C, Mauriège P, et al.  Comparison of the lipolytic effects of norepinephrine and BRL37344 in rat brown and white adipocytes. Obes Res. 1994;2:424–431
  39. Xu X, de Pergola G, Eriksson PS, et al.  Post receptors events involved in the up-regulation of beta-adrenergic receptor mediated lipolysis by testosterone in rat white adipocytes. Endocrinology. 1993;132:1651–1657
  40. Labrie F. At the cutting edge. Intracrinology. Mol Cell Endocrinol. 1991;78:C113–C118
  41. Mohan PF, Ihnen JS, Levin BE, et al.  Effects of dehydroepiandrosterone treatment in rats with diet-induced obesity. J Nutr. 1990;120:1103–1114
  42. Muller S, Cleary MP. Glucose metabolism in isolated adipocytes from lean and obese Zucker rats following treatment with dehydroepiandrosterone. Metabolism. 1985;34:278–284
  43. Coleman DL, Schwizer RW, Leiter EH. Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes/obesity mutants and in aged normal mice. Diabetes. 1984;33:26–32
  44. Kurzman ID, Panciera DL, Miller JB, et al.  The effect of dehydroepiandrosterone combined with a low-fat diet in spontaneously obese dogs: A clinical trial. Obes Res. 1998;6:20–28
  45. Després JP. The insulin-resistance-dyslipidemic syndrome of visceral obesity: Effect on patients' risk. Obes Res. 1998;6(suppl 1):8S–18S

☆ Supported by the Natural Sciences and Engineering Research Council of Canada and EndoRecherche.

☆☆ Address reprint requests to Pascale Mauriège, PhD, Division of Kinesiology, Department of Social and Preventive Medicine, P.E.P.S., Laval University, Ste-Foy, Québec, Canada G1K 7P4.

PII: S0026-0495(02)05259-9

doi: 10.1053/meta.2003.50043

Metabolism - Clinical and Experimental
Volume 52, Issue 3 , Pages 264-272 , March 2003

Article Tools